XOMA Corp (XOMA) - Total Assets
Based on the latest financial reports, XOMA Corp (XOMA) holds total assets worth $263.15 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of XOMA Corp for net asset value and shareholders' equity analysis.
XOMA Corp - Total Assets Trend (1985–2024)
This chart illustrates how XOMA Corp's total assets have evolved over time, based on quarterly financial data.
XOMA Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
XOMA Corp's total assets of $263.15 Million consist of 56.8% current assets and 43.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.9% |
| Accounts Receivable | $17.02 Million | 7.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.91 Million | 11.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1985–2024)
This chart illustrates how XOMA Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XOMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XOMA Corp's current assets represent 56.8% of total assets in 2024, a decrease from 60.4% in 1985.
- Cash Position: Cash and equivalents constituted 45.9% of total assets in 2024, down from 57.1% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 11.7% of total assets.
XOMA Corp Competitors by Total Assets
Key competitors of XOMA Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
XOMA Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.91 | 7.52 | 7.16 |
| Quick Ratio | 3.91 | 7.64 | 7.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.40 Million | $137.89 Million | $75.76 Million |
XOMA Corp - Advanced Valuation Insights
This section examines the relationship between XOMA Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.98 |
| Latest Market Cap to Assets Ratio | 1.54 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | $221.28 Million |
| Market Capitalization | $339.92 Million USD |
Valuation Analysis
Above Book Valuation: The market values XOMA Corp's assets above their book value (1.54x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: XOMA Corp's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for XOMA Corp (1985–2024)
The table below shows the annual total assets of XOMA Corp from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $221.28 Million | -5.56% |
| 2023-12-31 | $234.30 Million | +66.90% |
| 2022-12-31 | $140.38 Million | -15.72% |
| 2021-12-31 | $166.56 Million | +32.95% |
| 2020-12-31 | $125.28 Million | +30.88% |
| 2019-12-31 | $95.72 Million | +50.07% |
| 2018-12-31 | $63.78 Million | +41.95% |
| 2017-12-31 | $44.94 Million | +56.69% |
| 2016-12-31 | $28.68 Million | -61.70% |
| 2015-12-31 | $74.88 Million | -16.46% |
| 2014-12-31 | $89.63 Million | -33.50% |
| 2013-12-31 | $134.78 Million | +27.54% |
| 2012-12-31 | $105.68 Million | +35.42% |
| 2011-12-31 | $78.04 Million | +5.10% |
| 2010-12-31 | $74.25 Million | +40.56% |
| 2009-12-31 | $52.82 Million | -21.36% |
| 2008-12-31 | $67.17 Million | -20.80% |
| 2007-12-31 | $84.81 Million | -7.28% |
| 2006-12-31 | $91.48 Million | +26.04% |
| 2005-12-31 | $72.58 Million | +56.89% |
| 2004-12-31 | $46.26 Million | -61.08% |
| 2003-12-31 | $118.85 Million | +65.57% |
| 2002-12-31 | $71.78 Million | -16.64% |
| 2001-12-31 | $86.11 Million | +90.45% |
| 2000-12-31 | $45.21 Million | +59.76% |
| 1999-12-31 | $28.30 Million | -24.13% |
| 1998-12-31 | $37.30 Million | -42.44% |
| 1997-12-31 | $64.80 Million | +12.31% |
| 1996-12-31 | $57.70 Million | +41.08% |
| 1995-12-31 | $40.90 Million | -34.46% |
| 1994-12-31 | $62.40 Million | -33.69% |
| 1993-12-31 | $94.10 Million | -13.91% |
| 1992-12-31 | $109.30 Million | -29.16% |
| 1991-12-31 | $154.30 Million | +59.07% |
| 1990-12-31 | $97.00 Million | -12.22% |
| 1989-12-31 | $110.50 Million | +100.91% |
| 1988-12-31 | $55.00 Million | -17.29% |
| 1987-12-31 | $66.50 Million | +40.30% |
| 1986-12-31 | $47.40 Million | +218.12% |
| 1985-12-31 | $14.90 Million | -- |
About XOMA Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential… Read more